10x Genomics, Inc. Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. 10x Genomics, Inc. is a life sciences technology company providing integrated research solutions, including instruments (Chromium, Visium, Xenium), consumables, and software for single-cell and spatial analysis. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $150.8 million | $154.9 million |
| Products & Services Revenue | $149.9 million | $137.8 million |
| License & Royalty Revenue | $0.9 million | $17.1 million |
| Gross Profit | $106.2 million | $105.4 million |
| Gross Margin | 70% | 68% |
| Net Loss | $(13.5) million | $(34.4) million |
| Diluted EPS | $(0.10) | $(0.28) |
| Cash & Cash Equivalents | $490.3 million | $377.1 million |
| Marketable Securities | $49.6 million | $49.4 million |
| Operating Cash Flow | $26.1 million | $34.4 million |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue decreased 3% year-over-year, primarily driven by a 94% drop in license and royalty revenue. This decline is attributed to a one-time $16.8 million royalty payment received in Q1 2025 from a patent litigation settlement with Vizgen, Inc.
- Product Growth: Products and services revenue increased 9% to $149.9 million. Consumables revenue grew 13% (driven by a 31% increase in Spatial consumables), while instrument revenue declined 24%.
- Expense Reduction: Operating expenses decreased 15% to $123.2 million. Selling, general, and administrative (SG&A) expenses fell 26%, largely due to a $12.2 million reduction in outside legal expenses and lower stock-based compensation. Research and development (R&D) expenses decreased 12%.
- Profitability: Net loss improved significantly to $13.5 million from $34.4 million in the prior year, aided by lower operating expenses and a 2% increase in gross margin.
Guidance, Outlook, and Risks
- Outlook: Management expects revenues to moderately increase in 2026 compared to 2025, excluding $44.1 million of non-recurring license and royalty revenue recognized in 2025. Operating expenses are expected to modestly decrease in 2026, excluding $49.9 million in one-time gains recorded in 2025.
- Liquidity: The company holds approximately $539.8 million in cash and marketable securities. Management believes these resources are sufficient to meet cash needs for at least the next 12 months.
- Acquisitions & Contingencies: Following the 2025 acquisition of Scale Biosciences, Inc., the company made a Q1 2026 milestone payment of $10.0 million in cash and $8.7 million in stock. Up to $30.0 million in additional contingent consideration may be payable if future milestones are met.
- Legal Proceedings: Significant ongoing litigation includes:
- Parse Biosciences: Appeals pending regarding patent invalidity decisions; trial scheduled for August 2026.
- Curio Bioscience: Permanent injunction granted in Europe; trial scheduled for May 2026 in the U.S.
- Illumina: Two lawsuits filed in late 2025 regarding spatial and single-cell technologies; trials scheduled for 2028.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue growth excluding the one-time Vizgen royalty settlement from Q1 2025.
- Instrument Sales: Investigate the 24% year-over-year decline in instrument revenue and its potential impact on future consumables recurring revenue.
- Legal Exposure: Monitor the outcomes of the Parse, Curio, and Illumina litigation, as adverse rulings could impact market access or require significant settlements.
- Contingent Liabilities: Track the achievement of Scale Biosciences milestones, which could trigger up to $30.0 million in additional payments.
- Cash Burn: Assess the trajectory of operating cash flow relative to the $10–$15 million expected capital expenditures for the next 12 months.